within Pharmacolibrary.Drugs.ATC.S;

model S01EC04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0076,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01EC04</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Brinzolamide is a topical carbonic anhydrase inhibitor used for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. It is approved for ophthalmic use and lowers intraocular pressure by reducing aqueous humor formation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adults after ophthalmic (topical) administration.</p><h4>References</h4><ol><li><p>Iester, M (2008). Brinzolamide. <i>Expert opinion on pharmacotherapy</i> 9(4) 653–662. DOI:<a href=&quot;https://doi.org/10.1517/14656566.9.4.653&quot;>10.1517/14656566.9.4.653</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18312166/&quot;>https://pubmed.ncbi.nlm.nih.gov/18312166</a></p></li><li><p>Naageshwaran, V, et al., &amp; Del Amo, EM (2021). Comprehensive Ocular and Systemic Pharmacokinetics of Brinzolamide in Rabbits After Intracameral, Topical, and Intravenous Administration. <i>Journal of pharmaceutical sciences</i> 110(1) 529–535. DOI:<a href=&quot;https://doi.org/10.1016/j.xphs.2020.09.051&quot;>10.1016/j.xphs.2020.09.051</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33035542/&quot;>https://pubmed.ncbi.nlm.nih.gov/33035542</a></p></li><li><p>Naageshwaran, V, et al., &amp; Ranta, VP (2023). Topical pharmacokinetics of brinzolamide suspensions in rabbits and variability analysis for sample size and design considerations. <i>International journal of pharmaceutics</i> 642 123183–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2023.123183&quot;>10.1016/j.ijpharm.2023.123183</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37369289/&quot;>https://pubmed.ncbi.nlm.nih.gov/37369289</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01EC04;
